Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

Trevi Therapeutics (Nasdaq: TRVI) will report first quarter 2026 financial results and provide a corporate update on May 5, 2026.

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) will report first quarter 2026 financial results and provide a corporate update on May 5, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET covering the quarter ended March 31, 2026 and program updates for Haduvio.

Registration is via the Investors & News section or at ir.trevitherapeutics.com/news-events/events. Phone registrants receive unique call-in details by email. A webcast replay will be archived on the company website for 30 days after the event.

Argus Apr 29 session

-0.14% close to close Open Argus

Details

News Market Reaction – TRVI

On Apr 29, the first trading day after this news, TRVI closed 0.14% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Market Context

This announcement sets the timetable for Trevi’s first-quarter 2026 results and corporate update on ...

Analysis

This announcement sets the timetable for Trevi’s first-quarter 2026 results and corporate update on May 5, 2026 at 4:30 p.m. ET, without disclosing new financial or trial data. Historically, similar earnings-date notices have produced modest price moves. Investors may focus on upcoming details about cash usage, progress of Haduvio in IPF and other cough indications, and how planned Phase 2 and Phase 3 programs are advancing.

Key Figures

Earnings call date: May 5, 2026 Earnings call time: 4:30 p.m. ET Quarter end date: March 31, 2026 +1 more

Earnings call date

May 5, 2026

First quarter 2026 results and corporate update timing

Earnings call time

4:30 p.m. ET

Scheduled start time for the conference call and webcast

Quarter end date

March 31, 2026

Reporting period for first quarter 2026 financial results

Webcast replay window

30 days

Length of time replay will be available on company website

Previous Earnings date Reports

2 past events · Latest: Mar 10

Same Type 2 events

1. Mar 10

   Earnings date notice

   24h Move

   +1.5%

   Scheduled Q4 and full-year 2025 results call with business updates.

2. Nov 06

   Earnings date notice

   24h Move

   +0.0%

   Announced Q3 2025 results call and corporate update timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough, clinical-stage biopharmaceutical

4 terms

idiopathic pulmonary fibrosis medical

"chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

interstitial lung disease medical

"pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

refractory chronic cough medical

"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC)"

A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.

clinical-stage biopharmaceutical medical

"Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2026. 

Conference Call and Webcast
To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.     
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.    

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.   

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.  
  
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.  

Investor Contact   
Jonathan Carlson   
Trevi Therapeutics, Inc.   
(203) 654 3286   
IR@trevitx.com

Media Contact   
Rosalia Scampoli   
914-815-1465   
rscampoli@marketcompr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Trevi Therapeutics (TRVI) report Q1 2026 results and host the webcast?

Trevi will report Q1 2026 results and host a webcast on May 5, 2026 at 4:30 p.m. ET. According to the company, senior management will review the quarter ended March 31, 2026 and provide a corporate update during the call.

How can investors register for the TRVI May 5, 2026 conference call and webcast?

Investors can register via the company website at ir.trevitherapeutics.com/news-events/events. According to the company, phone participants receive an email with unique call-in details after registering for the live conference call and webcast.

Will Trevi Therapeutics (TRVI) provide a replay of the May 5, 2026 webcast?

Yes, a replay will be available for 30 days on the company website after the event. According to the company, an archived audio webcast will be posted in the Investors & News section for on-demand access.

What topics will Trevi Therapeutics (TRVI) cover during the May 5, 2026 call?

The company will review Q1 2026 financial results and provide a corporate update, including program information for Haduvio. According to the company, senior management will discuss the quarter ended March 31, 2026 and program developments.

What is Haduvio and will it be discussed in the TRVI May 5, 2026 update?

Haduvio is oral nalbuphine ER being developed for chronic cough in IPF, non-IPF ILD, and RCC. According to the company, program updates for Haduvio will be part of the corporate update during the May 5 call.